Literature DB >> 11350127

Human semaphorin 6B [(HSA)SEMA6B], a novel human class 6 semaphorin gene: alternative splicing and all-trans-retinoic acid-dependent downregulation in glioblastoma cell lines.

R G Correa1, R M Sasahara, M H Bengtson, M L Katayama, A C Salim, M M Brentani, M C Sogayar, S J de Souza, A J Simpson.   

Abstract

We have identified a novel human gene related to the class 6 semaphorin family of axon guidance molecules, termed human semaphorin 6B or (HSA)SEMA6B. Two splicing variants of this gene were identified by RT-PCR: (HSA)SEMA6B.1 (short isoform) and (HSA)SEMA6B.2 (longer isoform). Computational analysis suggests that these isoforms correspond to putative secreted and transmembranous semaphorins, respectively. The levels of (HSA)SEMA6B expression were evaluated by Northern blot analysis in different tissues and in some pathological and pharmacological conditions. We observed that (HSA)SEMA6B is highly expressed in human brain and at lower levels in a variety of other tissues. Interestingly, the (HSA)SEMA6B transcript was downregulated in two different human glioblastoma cell lines (T98G and A172) upon prolonged treatment with all-trans-retinoic acid, an anti-tumor and differentiation-inducing agent. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11350127     DOI: 10.1006/geno.2001.6525

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  12 in total

1.  Semaphorin 5A and plexin-B3 inhibit human glioma cell motility through RhoGDIalpha-mediated inactivation of Rac1 GTPase.

Authors:  Xinhua Li; Alan Yiu Wah Lee
Journal:  J Biol Chem       Date:  2010-08-09       Impact factor: 5.157

Review 2.  Semaphorin signals on the road to cancer invasion and metastasis.

Authors:  Sabrina Rizzolio; Luca Tamagnone
Journal:  Cell Adh Migr       Date:  2007-04-13       Impact factor: 3.405

Review 3.  Transmembrane semaphorins: Multimodal signaling cues in development and cancer.

Authors:  Sreeharsha Gurrapu; Luca Tamagnone
Journal:  Cell Adh Migr       Date:  2016-06-13       Impact factor: 3.405

4.  The class 6 semaphorin SEMA6A is induced by interferon-gamma and defines an activation status of langerhans cells observed in pathological situations.

Authors:  Gregory Gautier; Blandine de Saint-Vis; Brigitte Sénéchal; Jean-Jacques Pin; Elizabeth E M Bates; Christophe Caux; Frédéric Geissmann; Pierre Garrone
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

5.  The role of semaphorins and their receptors in gliomas.

Authors:  Janice Wai Sze Law; Alan Yiu Wah Lee
Journal:  J Signal Transduct       Date:  2012-09-23

6.  A Frameshift Variant in the SEMA6B Gene Causes Global Developmental Delay and Febrile Seizures.

Authors:  Li Shu; Yuchen Xu; Qi Tian; Yuanyuan Chen; Yaqin Wang; Hui Xi; Hua Wang; Neng Xiao; Xiao Mao
Journal:  Neurosci Bull       Date:  2021-06-10       Impact factor: 5.271

Review 7.  Role of Semaphorins in Ischemic Stroke.

Authors:  Huaping Du; Yuan Xu; Li Zhu
Journal:  Front Mol Neurosci       Date:  2022-03-08       Impact factor: 5.639

8.  SEMA6B Overexpression Predicts Poor Prognosis and Correlates With the Tumor Immunosuppressive Microenvironment in Colorectal Cancer.

Authors:  Tiegang Li; Zheng Yan; Weiqi Wang; Rixin Zhang; Wenqiang Gan; Silin Lv; Zifan Zeng; Yufang Hou; Min Yang
Journal:  Front Mol Biosci       Date:  2021-12-06

9.  Zonisamide-responsive myoclonus in SEMA6B-associated progressive myoclonic epilepsy.

Authors:  Rebecca Herzog; Yorck Hellenbroich; Norbert Brüggemann; Katja Lohmann; Mona Grimmel; Tobias B Haack; Sarah von Spiczak; Alexander Münchau
Journal:  Ann Clin Transl Neurol       Date:  2021-06-06       Impact factor: 4.511

10.  NOVA regulates Dcc alternative splicing during neuronal migration and axon guidance in the spinal cord.

Authors:  Janelle C Leggere; Yuhki Saito; Robert B Darnell; Marc Tessier-Lavigne; Harald J Junge; Zhe Chen
Journal:  Elife       Date:  2016-05-25       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.